Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study

Wanzi Chen; Hangmin Liu; Pengcheng Wang; Guoping Li

doi:10.21037/tcr-21-882

Clinical and biological features of mantle cell lymphoma patients with co-expression of CD10 and BCL-6: a retrospective study

Transl Cancer Res. 2021 Nov;10(11):4786-4793. doi: 10.21037/tcr-21-882.

Authors

Wanzi Chen¹, Hangmin Liu², Pengcheng Wang³, Guoping Li³

Affiliations

¹ Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
² Clinical Laboratory, Fujian Medical University Union Hospital, Fuzhou, China.
³ Department of pathology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Abstract

Background: Mantle cell lymphoma (MCL) with co-expression of CD10 and BCL-6 was scarcely reported, and its biological features were largely remained unknown. Thus, this study aimed to describe the clinical and biological features, as well as outcome of MCL patients with co-expression of CD10 and BCL-6.

Methods: A total of 104 cases of MCL who were admitted to our hospital between January 2011 and October 2018 were recruited. Those patients were diagnosed according to the 2016 World Health Organization (WHO) classification system for tumors of the hematopoietic and lymphoid tissues, in compliance with the results of cytomorphology and immunohistochemical analysis. Patients were followed up through telephone interviews, medical records. Differences in age, gender, leukocyte count, lactate dehydrogenase (LDH) level, beta-2 microglobulin (β2-MG) level and results of immunohistochemistry were analyzed. Then the event-free survival (EFS) rate and overall survival (OS) rate were performed by the Kaplan-Meier method and log-rank test.

Results: The results showed that, in total, 5 patients had superficial lymph node enlargement, 2 patients suffered from abdominal discomfort, and 1 patient's red blood cell (RBC) count was abnormal at the time of diagnosis. All patients were in stage IV, 75% had bone marrow involvement, and 75% and 100% of patients had elevated levels of LDH and β2-MG, respectively. Three classic genes and five variants were involved in the 8 patients. MCL patients with the co-expression of CD10 and BCL-6 had higher Ki-67 index, white blood cell (WBC) count, LDH level, and β2-MG level than those of without co-expression of CD10 and BCL-6 (P=0.025, 0.038, 0.015, and 0.021, respectively). Besides, MCL patients with CD10 and BCL-6 co-expression had shorter OS and EFS (χ²=6.401 and 5.975; P=0.011 and 0.015, respectively), indicating patients' susceptibility to get complex karyotype and TP53 abnormality.

Conclusions: MCL patients with co-expression of CD10 and BCL-6 were more likely to have bone marrow involvement, higher Ki-67 index, increased WBC count, and elevated levels of LDH and β2-MG at the time of diagnosis, then might has complex cytogenetic and poor prognosis.

Keywords: BCL-6; CD10; Mantle cell lymphoma (MCL); cytogenetic factors; immunohistochemistry.